Compare Merck & Co., Inc. (MRK) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Tesla, Inc. — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Tesla, Inc. trades at $382.7 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 4.2× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Tesla, Inc. for 88 Days on average.
| MRK | TSLA | |
|---|---|---|
Market Cap | $351.28B | $1.48T |
Volume | 7,969,665 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $489.88 |
52-Week Low | $82.49 | $298.16 |
Typical Hold Time | 98 Days | 88 Days |
Enterprise Value | $398.04B | $1.45T |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Tesla (TSLA) trades at $375.03, down 0.68% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed earnings, beating in Q4 2025 and Q1 2026 but missing in Q2 2026, with revenue at $94.83B in 2025 and a net income margin of 4%. Analyst consensus is a Buy with a $441.36 price target, and recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch.
Tesla's outlook balances innovation in autonomy and energy against near-term execution risks and high valuation multiples. The stock offers growth potential from AI and robotics expansion, but faces headwinds from competitive pressures and margin compression. Investors should weigh long-term disruptive potential against current profitability challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
